Merck & Company Inc (MRK)vsSanofi ADR (SNY)
MRK
Merck & Company Inc
$144.85
+0.64%
HEALTHCARE · Cap: $355.10B
SNY
Sanofi ADR
$42.77
+0.12%
HEALTHCARE · Cap: $102.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 36% more annual revenue ($66.57B vs $48.92B). SNY leads profitability with a 8.1% profit margin vs 4.8%. MRK appears more attractively valued with a PEG of 2.64. SNY earns a higher WallStSmart Score of 49/100 (D+).
MRK
Hold36
out of 100
Grade: F
SNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.85
$62.01 premium
Margin of Safety
+7.8%
Fair Value
$51.00
Current Price
$42.77
$8.23 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 21.0%
Generating 3.9B in free cash flow
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
ROE of 5.7% — below average capital efficiency
Expensive relative to growth rate
Earnings declined 91.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Revenue growth of 14.6% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : SNY
The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
SNY carries more volatility with a beta of 0.28 — expect wider price swings.
SNY is growing revenue faster at 14.6% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SNY scores higher overall (49/100 vs 36/100) and 14.6% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?